White Papers

Home / Intelligence / White Papers


Valuing an Early-Stage Asset in Pharma and Biotech

In 2018, Trinity Life Sciences published a white paper titled, How to Approach Asset Valuation in Pharma & Biotech: Putting a price tag on emerging therapies. At the time, pharma and biotech firms were seeing venture investment growth of ~20% per year. This trend has only accelerated alongside the value of co-developments, partnerships, joint ventures, licensing agreements and other deals nearly doubling from 2019 to 2020. Quantifying the value of underlying assets throughout the clinical development process remains vital to…

Read Now

Empowering the Next-Generation Launch Model

The pharma industry has seen dramatic shifts in scientific innovation over the last decade with a trend toward orphan markets, personalized medicine, higher priced products and new modalities including cell and gene therapies, oligonucleotides and others. COVID served to further accelerate scientific innovation, driving a near record-breaking number of FDA approvals, astronomical venture capital funding and remarkably rapid development and rollout of ground-breaking products (including anti-virals, novel antibodies and mRNA vaccines). However, as Trinity Life Sciences discussed one year ago,…

Read Now

Reimagining Work Models in the Life Sciences: Implications for the Future of Work

The Changing Work Model for Life Sciences. When considering a work environment that will be sustainable in this new working world, life sciences companies have been examining policies and addressing how and where employees should work though lack objective sources of data to make informed decisions. The life sciences industry as a whole lacks work-model data. Like many organizations globally, certain work-model assumptions need to be validated or debunked. For example, Employees should be at company headquarters if or when…

Read Now

Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR

The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. To understand the implications of this growth, the Trinity Life Sciences Evidence Strategy team sought to gain a multi-disciplinary view on where and how HEOR experts see the field evolving and to better understand how HEOR capabilities can be…

Read Now

The Future of Leading Hybrid Conferences

The Example of ASH 2021 Medical conferences are designed to bring bright minds together and pique interest and curiosity. The American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), European Society for Medical Oncology (ESMO), Gene Therapy for Rare Disorders, and other medical conferences play an important role in disseminating clinical and scientific information. Attendees range from physicians to investors, and the conferences provide a forum for peer-to-peer interactions, exposure to current research, innovative trends and an environment…

Read Now

Diversity in Clinical Trials Participation: A Life Sciences Perspective

Providing optimal care to all patients is an imperative that unites the various, interconnected parts of the medical field, from primary care to the pharmaceutical industry to the work of large academic medical centers. Over the past 30 years, there have been exceptional advances in care, treatment, diagnostics, and early identification of disease. Unfortunately, even with these many technological advances, addressing the importance of diversity has been lagging. Since the advent of clinical trials, recruitment has been largely centered on…

Read Now

Women Representation in Life Science Consulting Leadership

Over the past few years, there has been a spotlight on gender representation in leadership in a wide range of industries. Women are underrepresented in healthcare and biotech companies, despite evidence showing that companies that don’t have equitable representation perform worse compared to those that do. While this is recognized, there is a lack of understanding about the scope of the problem within life sciences consulting. In general, there is a lack of transparency on these issues, with a resulting…

Read Now

Why you should consider Patient Finding for physician targeting

Patient Finding is an innovative tool to improve customer targeting that can be implemented fairly quickly, without a lot of organizational disruption, retraining, or complex data integration. It is a worthwhile addition to your portfolio of targeting methods. For appropriate brands, Patient Finding can provide a significant competitive advantage. As it becomes more widely used by the pharma industry, late adopters may find themselves at a competitive disadvantage. Complete the form below to access “Why you should consider Patient Finding…

Read Now

Navigating the New World of Virtual Conferences

The Example of ASCO 2021 While people were expecting to return to in-person conferences soon, the emergence of the Delta variant and the possibility of future unknown variants, combined with uneven vaccination rates, has created significant uncertainty about how soon that can happen. Trinity Life Sciences wanted to understand what perceptions medical conference attendees had of the new virtual conference world, what advantages and disadvantages they saw in it, and how manufacturers performed at engaging their audiences. We performed a…

Read Now

The 2020 Dichotomy: An Analysis of the COVID-19 Launch Class and How Commercial Innovation Failed to Keep Pace with Scientific Progress

Despite the challenges the COVID-19 pandemic created, 2020 was an exceptional year for the biopharma industry. The race to develop effective treatments and vaccines for COVID elevated the public’s perception of biotechnology, and, for many, the industry provided a source of hope during the pandemic. As early-stage venture capitalist Bruce Booth observed in his review of 2020, investors’ enthusiasm sent biotech indexes to all-time highs, boosted the performance of IPOs and accelerated venture capital funding. The NASDAQ Biotech Index finished…

Read Now